SEC Form 4 · accession 0001171843-17-001205
Anika Therapeutics, Inc. · ANIK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward S. Ahn
Officer — Chief Tech & Strategy Officer
Period of report
Feb 24, 2017
Accepted (ET)
Feb 28, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000898437
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 24, 2017 | S | 640 | $49.47 | D | 7,260 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1,F3 | $38.11 | Feb 24, 2017 | A | 11,500 | A | — | Feb 4, 2026 | Common Stock | 11,500 | 11,500 | D |
Explanation of responses
- F1The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3.
- F2On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3.
- F3The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020.